{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:37:55Z","timestamp":1761061075225},"reference-count":27,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2020]]},"DOI":"10.3164\/jcbn.20-17","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T22:06:18Z","timestamp":1593468378000},"page":"332-337","source":"Crossref","is-referenced-by-count":6,"title":["Influence of acotiamide on &lt;sup&gt;13&lt;\/sup&gt;C-urea breath test for &lt;i&gt;Helicobacter pylori&lt;\/i&gt; diagnosis"],"prefix":"10.3164","volume":"67","author":[{"given":"Kazuhiro","family":"Mizukami","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Katsuta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Takada Chuo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinari","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Hirashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayoshi","family":"Okimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Takada Chuo Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ichikawa H, Sugimoto M, Sakao Y, et al. Eradication therapy for <i>Helicobacter pylori<\/i> infection improves nutrition status in Japanese hemodialysis patients: a pilot study. J Clin Biochem Nutr 2019; 64: 91\u201395.","DOI":"10.3164\/jcbn.18-61"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377\u20131390.","DOI":"10.1053\/j.gastro.2006.03.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466\u20131479.","DOI":"10.1053\/j.gastro.2005.11.059"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Moay.yedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; (4): CD001960.","DOI":"10.1002\/14651858.CD001960.pub3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Talley NJ, Meineche-Schmidt V, Par\u00e9 P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055\u20131065.","DOI":"10.1046\/j.1365-2036.1998.00410.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of <i>Helicobacter pylori<\/i> during treatment with omeprazole. Gut 1995; 36: 12\u201316.","DOI":"10.1136\/gut.36.1.12"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for <i>Helicobacter pylori<\/i>. Ann Intern Med 1998; 129: 547\u2013550.","DOI":"10.7326\/0003-4819-129-7-199810010-00007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005\u20131009.","DOI":"10.1111\/j.1572-0241.2003.07426.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Matsuzaki J, Suzuki H, Asakura K, et al. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol Motil 2012; 24: 325\u2013e164.","DOI":"10.1111\/j.1365-2982.2011.01859.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Manabe N, Haruma K, Hata J, et al. Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? Scand J Gastroenterol 2010; 45: 567\u2013572.","DOI":"10.3109\/00365521003592663"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Tack J, Talley NJ. Functional dyspepsia\u2014symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 2013; 10: 134\u2013141.","DOI":"10.1038\/nrgastro.2013.14"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43: 2028\u20132033.","DOI":"10.1023\/A:1018803129779"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 94\u201399.","DOI":"10.1016\/0016-5085(86)90444-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012; 61: 821\u2013828.","DOI":"10.1136\/gutjnl-2011-301454"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tack J, Pokrotnieks J, Urbonas G, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)\u2014results from the European phase 3 open-label safety trial. Neurogastroenterol Motil 2018; 30: e13284.","DOI":"10.1111\/nmo.13284"},{"key":"16","unstructured":"16 Ueda M, Iwasaki E, Suzuki H. Profile of acotiamide in the treatment of functional dyspepsia. Clin Exp Gastroenterol 2016; 9: 83\u201388."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 2011; 84: 261\u2013268.","DOI":"10.1159\/000332404"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Murakami K, Sato R, Okimoto T, et al. Influence of anti-ulcer drugs used in Japan on the result of <sup>13<\/sup>C-urea breath test for the diagnosis of <i>Helicobacter pylori<\/i> infection. J Gastroenterol 2003; 38: 937\u2013941.","DOI":"10.1007\/s00535-003-1176-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Savarino V, Bisso G, Pivari M, et al. Effect of gastric acid suppression on <sup>13<\/sup>C-urea breath test: comparison of ranitidine with omeprazole. Aliment Pharmacol Ther 2000; 14: 291\u2013297.","DOI":"10.1046\/j.1365-2036.2000.00721.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Connor SJ, Seow F, Ngu MC, Katelaris PH. The effect of dosing with omeprazole on the accuracy of the <sup>13<\/sup>C-urea breath test in <i>Helicobacter pylori<\/i>-infected subjects. Aliment Pharmacol Ther 1999; 13: 1287\u20131293.","DOI":"10.1046\/j.1365-2036.1999.00601.x"},{"key":"21","unstructured":"21 Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of <i>Helicobacter pylori<\/i>: unique action selective for <i>H. pylori<\/i> cells. Antimicrob Agents Chemother 1993; 37: 769\u2013774."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Graham DY, Opekun AR, Jogi M, et al. False negative urea breath tests with H2-receptor antagonists: interactions between <i>Helicobacter pylori<\/i> density and pH. Helicobacter 2004; 9: 17\u201327.","DOI":"10.1111\/j.1083-4389.2004.00191.x"},{"key":"23","unstructured":"23 Chey WD, Woods M, Scheiman JM, Nostrant TT, DelValle J. Lansoprazole and ranitidine affect the accuracy of the <sup>14<\/sup>C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997; 92: 446\u2013450."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Parente F, Sainaghi M, Sangaletti O, et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the <sup>13<\/sup>C-urea breath test. Aliment Pharmacol Ther 2002; 16: 553\u2013557.","DOI":"10.1046\/j.1365-2036.2002.01192.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42: 719\u2013730.","DOI":"10.1111\/apt.13325"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ohkuma K, Iida H, Inoh Y, et al. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr 2018; 63: 80\u201383.","DOI":"10.3164\/jcbn.17-128"},{"key":"27","unstructured":"27 Astellas Pharma Inc. Acofide<sup>\u00ae<\/sup> Tablets 100 mg Interview form. Revised: Jun 2014 (Ver. 5)."}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/67\/3\/67_20-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:52:34Z","timestamp":1604721154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/67\/3\/67_20-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.20-17","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}